GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » PositiveID Corp (OTCPK:PSID) » Definitions » Return-on-Tangible-Equity

PositiveID (PositiveID) Return-on-Tangible-Equity : 0.00% (As of Mar. 2018)


View and export this data going back to 2007. Start your Free Trial

What is PositiveID Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. PositiveID's annualized net income for the quarter that ended in Mar. 2018 was $-11.43 Mil. PositiveID's average shareholder tangible equity for the quarter that ended in Mar. 2018 was $-10.94 Mil. Therefore, PositiveID's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2018 was N/A%.

The historical rank and industry rank for PositiveID's Return-on-Tangible-Equity or its related term are showing as below:

PSID's Return-on-Tangible-Equity is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -1.945
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

PositiveID Return-on-Tangible-Equity Historical Data

The historical data trend for PositiveID's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PositiveID Return-on-Tangible-Equity Chart

PositiveID Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

PositiveID Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PositiveID's Return-on-Tangible-Equity

For the Diagnostics & Research subindustry, PositiveID's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PositiveID's Return-on-Tangible-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, PositiveID's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where PositiveID's Return-on-Tangible-Equity falls into.



PositiveID Return-on-Tangible-Equity Calculation

PositiveID's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2017 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2017 )  (A: Dec. 2016 )(A: Dec. 2017 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2017 )  (A: Dec. 2016 )(A: Dec. 2017 )
=-8.567/( (-10.155+-10.398 )/ 2 )
=-8.567/-10.2765
=N/A %

PositiveID's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2018 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2018 )  (Q: Dec. 2017 )(Q: Mar. 2018 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2018 )  (Q: Dec. 2017 )(Q: Mar. 2018 )
=-11.432/( (-10.398+-11.477)/ 2 )
=-11.432/-10.9375
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2018) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


PositiveID  (OTCPK:PSID) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


PositiveID Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of PositiveID's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


PositiveID (PositiveID) Business Description

Traded in Other Exchanges
N/A
Address
1690 South Congress Avenue, Suite 201, Delray Beach, FL, USA, 33445
PositiveID Corp is a life science tools and diagnostics company. It specializes in the biological detection and molecular diagnostic systems for homeland defense and the global healthcare market. The business activity of the firm includes the development of microfluidic systems in order to detect biological threats and outbreaks, whether airborne, in a healthcare setting, or at the point of need through its subsidiary. Further, it is also involved in the development of FireflyDX family of products, automated pathogen detection system for rapid diagnostics, both for clinical and point-of-need applications. In addition, it also manufactures specialty technology vehicles focused primarily on mobile laboratory and communications applications. All the activities are carried out through the US.
Executives
Ned L Siegel director 600 WILSHIRE BOULEVARD, LOS ANGELES CA 90017
Michael E Krawitz director 1690 S CONGRESS AVE, STE 201, DELRAY BEACH FL 33445
Barry M Edelstein director 1100 GREEN VALLEY ROAD, BRYN MAWR PA 19010
Scott R Silverman other: Former 10% Owner
Marxe Austin W & Greenhouse David M 10 percent owner C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Weaver Constance K director 2900 ESPERANZA CROSSING, 2ND FLOOR, AUSTIN TX 78758
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105

PositiveID (PositiveID) Headlines

From GuruFocus

PositiveID's Chairman and CEO Addresses Stockholders

By Marketwired Marketwired 04-26-2018